<DOC>
	<DOC>NCT00302211</DOC>
	<brief_summary>The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil therapy for pulmonary arterial hypertension (PAH). The study will also examine whether patients on sildenafil can reduce the number of iloprost inhalations from the approved 6 doses per day to 4 doses per day.</brief_summary>
	<brief_title>The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Aged 1285 years; of either gender. Confirmed PAH due to idiopathic pulmonary arterial hypertension (IPAH) or familial pulmonary arterial hypertension (FPAH). 6minute walk distance (6MWD) between 100450 meters at screening. On a stable dose of sildenafil, with or without Bosentan. Any treatment for PAH with prostacyclins, prostacyclin analogues, endothelin1 antagonists, or phosphodiesterase5 (PDE5) inhibitors other than sildenafil within the past 12 weeks. Pulmonary hypertension due to conditions other than those stated in inclusion criteria. Additional PAH medications added within the past 12 weeks</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>PAH</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>